GLP-1 Medicines and PCOS: What Evidence Exists So Far?

Polycystic ovary syndrome (PCOS) can involve irregular periods, androgen-related symptoms like acne or extra hair growth, insulin resistance and fertility concerns. Online posts sometimes present GLP-1 medicines as a complete fix for PCOS, but the evidence is more nuanced. Research has looked at weight, metabolic markers, hormones and menstrual patterns, mostly in small, short and quite varied studies.

What studies have actually looked at

Because GLP-1 medicines influence appetite, body weight and glucose regulation, researchers have tested them in people with PCOS, usually in women who also have overweight or obesity. Here's roughly where the published evidence sits:

• Hormones and insulin resistance. A 2026 meta-analysis in Cureus pooled four small randomized trials (218 women, each lasting just 12 weeks) comparing GLP-1 medicines with metformin. GLP-1 groups had somewhat lower testosterone and other androgens and better insulin-resistance scores, but the results varied a lot between studies and the authors note that long-term data on cycles, ovulation and fertility are still lacking.
• Menstrual cycles. A 2026 meta-analysis of seven trials of liraglutide (an older daily GLP-1) in 330 women with PCOS and overweight or obesity found more frequent periods, lower BMI and better insulin sensitivity than comparison treatments. Ovulation and pregnancy could not be pooled because too few studies reported them.
• Pregnancy rates. A 2023 meta-analysis of 11 small trials (840 women) reported a higher natural pregnancy rate with GLP-1 medicines, but no clear difference in overall or IVF pregnancy rates. That's a signal worth studying, not proof.

Many of these trials used older GLP-1 medicines such as liraglutide or exenatide rather than today’s weekly options, and it's hard to tell how much of any change comes from the medicine itself versus weight loss.

Is a GLP-1 medicine an approved PCOS treatment?

Not in the US, as of October 2026. Wegovy, Zepbound and other GLP-1 medicines are approved for specific uses such as type 2 diabetes or chronic weight management, and some people with PCOS qualify for those uses. That doesn't make them approved treatments for PCOS itself, irregular periods or infertility. Indications differ by country, so the current local label and your clinician's guidance matter.

Why pregnancy plans matter

This part is easy to overlook. The US Wegovy label advises stopping it at least 2 months before a planned pregnancy because semaglutide stays in the body a long time, and it should be stopped if pregnancy is recognized. The Zepbound label says tirzepatide may make birth-control pills less effective, especially after starting and after each dose increase, and advises a non-oral method or a backup barrier method for 4 weeks after each of those steps. Instructions differ by product, so one label can't be applied to another.

If cycles become more regular, ovulation may return, and that can mean pregnancy is possible sooner than expected. More regular cycles still don't guarantee pregnancy. Anyone who could become pregnant should talk through contraception, timing and ongoing PCOS care with a qualified clinician, and shouldn't start or stop a medicine to influence fertility on their own.

What to ask your clinician

Ask which PCOS symptoms and metabolic goals are being treated, whether the evidence fits someone like you, how pregnancy plans change your options, and what monitoring makes sense. Keeping a simple log of cycles and symptoms next to weight can make that conversation easier, and our guide to tracking progress beyond the scale has ideas. A gynecologist, endocrinologist or primary-care clinician can help coordinate care.

The fair takeaway: GLP-1 research in PCOS is promising for some metabolic and cycle measures, and may be relevant for selected patients. It isn't a universal PCOS cure or a promise of better fertility.